Literature DB >> 24477590

TLR3 plays significant roles against hepatitis B virus.

Masoud Karimi-Googheri1, Mohammad Kazemi Arababadi.   

Abstract

Hepatitis B virus (HBV) as the main prevalent infectious agent, play important roles in inducing severe liver diseases. Previous studies demonstrated that during prolonged forms of hepatitis B infection including chronic, asymptomatic and occult forms, patients are unable to eradicate HBV from hepatocytes completely. The main mechanisms responsible for development of the forms of hepatitis B are yet to be identified. Investigators suggested that the various genetic and immunological parameters of the patients may are responsible for resulting in the prolonged infection forms. It has been evidenced that TLRs play key roles in inducing appropriate immune responses, against viral infections. Therefore, these molecules can be considered as crucial sensors for HBV detection to induce immune responses against this virus. It has also been documented that the TLR3 detects intracellular viral dsRNA and subsequently activates NF-κB via the TRIF pathway. Therefore, impaired TLR3 expression may result in inappropriate immune responses against HBV which is reported in prolonged forms of hepatitis B. This review collected the recent information regarding the important roles of TLR3 in immune responses against HBV and also the status of TLR3 expression and its genetic variations in prolonged forms of HBV infections.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477590     DOI: 10.1007/s11033-014-3190-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  67 in total

1.  Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection.

Authors:  Mohammed Alsharifi; Mario Lobigs; Matthias Regner; Eva Lee; Aulikki Koskinen; Arno Müllbacher
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

2.  Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.

Authors:  Jungwoo Choe; Matthew S Kelker; Ian A Wilson
Journal:  Science       Date:  2005-06-16       Impact factor: 47.728

3.  Suppression of MyD88- and TRIF-dependent signaling pathways of Toll-like receptor by (-)-epigallocatechin-3-gallate, a polyphenol component of green tea.

Authors:  Hyung S Youn; Joo Y Lee; Shin I Saitoh; Kensuke Miyake; Keon W Kang; Yong J Choi; Daniel H Hwang
Journal:  Biochem Pharmacol       Date:  2006-08-04       Impact factor: 5.858

4.  TLR3 signaling in a hepatoma cell line is skewed towards apoptosis.

Authors:  Elina Khvalevsky; Ludmila Rivkin; Jacob Rachmilewitz; Eithan Galun; Hilla Giladi
Journal:  J Cell Biochem       Date:  2007-04-01       Impact factor: 4.429

5.  Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3.

Authors:  Shiyan Yu; Jieliang Chen; Min Wu; Hui Chen; Nobuyuki Kato; Zhenghong Yuan
Journal:  J Gen Virol       Date:  2010-04-07       Impact factor: 3.891

6.  Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.

Authors:  M F Sprinzl; C Russo; J Kittner; S Allgayer; A Grambihler; B Bartsch; A Weinmann; P R Galle; M Schuchmann; U Protzer; T Bauer
Journal:  J Viral Hepat       Date:  2013-11-19       Impact factor: 3.728

7.  mRNA is an endogenous ligand for Toll-like receptor 3.

Authors:  Katalin Karikó; Houping Ni; John Capodici; Marc Lamphier; Drew Weissman
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

Review 8.  Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN.

Authors:  Necati Ormeci
Journal:  Fundam Clin Pharmacol       Date:  2003-12       Impact factor: 2.748

9.  Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B.

Authors:  Masaru Enomoto; Shuhei Nishiguchi; Akihiro Tamori; Sawako Kobayashi; Hiroki Sakaguchi; Susumu Shiomi; Soo Ryang Kim; Hirayuki Enomoto; Masaki Saito; Hiroyasu Imanishi; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-08-02       Impact factor: 7.527

10.  Non-association of IL-12 +1188 and IFN-γ +874 polymorphisms with cytokines serum level in occult HBV infected patients.

Authors:  Mohammad K Arababadi; Ali A Pourfathollah; Abdollah Jafarzadeh; Gholamhossein Hassanshahi; Saeed Daneshmandi; Ali Shamsizadeh; Derek Kennedy
Journal:  Saudi J Gastroenterol       Date:  2011 Jan-Feb       Impact factor: 2.485

View more
  10 in total

1.  Evaluating Effect of Mesenchymal Stem Cells on Expression of TLR2 and TLR4 in Mouse DCs.

Authors:  Mohammad Hossein Karimi; Zahra Barzkar; Maryam Babaee; Majid Naghdi
Journal:  Adv Pharm Bull       Date:  2016-06-30

2.  Down-regulation of transforming growth factor-beta and interleukin-6 serum levels in the idiopathic chronic obstructive pulmonary disease.

Authors:  Reza Bahramabadi; Hassan Yousefi-Daredor; Sahar Rezaeinejad; Mohammadtaghi Rezayati; Mohammad Kazemi Arababadi
Journal:  Am J Clin Exp Immunol       Date:  2022-06-15

Review 3.  Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses.

Authors:  Yujuan Chen; Junhong Lin; Yao Zhao; Xianping Ma; Huashan Yi
Journal:  J Zhejiang Univ Sci B       Date:  2021-08-15       Impact factor: 3.066

4.  Regulation of TLR3 Activation by S100A9.

Authors:  Su-Yu Tsai; Jesus A Segovia; Te-Hung Chang; Niraj K Shil; Swechha M Pokharel; T R Kannan; Joel B Baseman; Joan Defrêne; Nathalie Pagé; Annabelle Cesaro; Philippe A Tessier; Santanu Bose
Journal:  J Immunol       Date:  2015-09-18       Impact factor: 5.422

5.  TLR3 Plays Significant Roles against HBV-Associated HCC.

Authors:  Xiao-Lan Chen; Yu-Yin Xu; Li Chen; Gui-Lan Wang; Yin Shen
Journal:  Gastroenterol Res Pract       Date:  2015-04-23       Impact factor: 2.260

6.  Up-regulation of RIP1 and IPS-1 in chronic HBV infected patients.

Authors:  Minoo Safari-Arababadi; Mohammad Hossein Modarressi; Mohammad Kazemi Arababadi
Journal:  Genet Mol Biol       Date:  2019-08-19       Impact factor: 1.771

Review 7.  CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance.

Authors:  Guillem Montamat; Cathy Leonard; Aurélie Poli; Ludger Klimek; Markus Ollert
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

8.  Interleukin 17A: A Potential Target for Its Plausible Roles in the Pathogenesis of Idiopathic Epistaxis.

Authors:  Reza Nosratabadi; Ali Golshiri-Isfahani; Soheila Rahmanzadeh-Shahi; Gholamreza Asadikaram; Mohammad Kazemi Arababadi
Journal:  Iran J Otorhinolaryngol       Date:  2022-01

9.  Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen.

Authors:  Catherine Isabell Real; Mengji Lu; Jia Liu; Xuan Huang; Martin Trippler; Markus Hossbach; Jochen Deckert; Kerstin Jahn-Hofmann; Ludger Markus Ickenstein; Matthias Johannes John; Kathrin Gibbert; Ulf Dittmer; Hans-Peter Vornlocher; Reinhold Schirmbeck; Guido Gerken; Joerg Friedrich Schlaak; Ruth Broering
Journal:  Sci Rep       Date:  2016-04-28       Impact factor: 4.379

10.  HCFC2 is needed for IRF1- and IRF2-dependent Tlr3 transcription and for survival during viral infections.

Authors:  Lei Sun; Zhengfan Jiang; Victoria A Acosta-Rodriguez; Michael Berger; Xin Du; Jin Huk Choi; Jianhui Wang; Kuan-Wen Wang; Gokhul K Kilaru; Jennifer A Mohawk; Jiexia Quan; Lindsay Scott; Sara Hildebrand; Xiaohong Li; Miao Tang; Xiaoming Zhan; Anne R Murray; Diantha La Vine; Eva Marie Y Moresco; Joseph S Takahashi; Bruce Beutler
Journal:  J Exp Med       Date:  2017-10-02       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.